Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 311Leukemia, Lymphocytic, Chronic, B-Cell 108Myelodysplastic Syndromes 63Leukemia 43Recurrence 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Neoplasms 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Non-Hodgkin 21Hematologic Neoplasms 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Leukemia, Myeloid 11Neoplasm, Residual 10Myeloproliferative Disorders 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Multiple Myeloma 9Lymphoma, Mantle-Cell 8Lymphoma 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Chromosome 17 deletion 6Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia, B-Cell 5Burkitt Lymphoma 5Primary Myelofibrosis 4GATA2 Deficiency 4Blast Crisis 4

Interventions

fludarabine 6Tacrolimus 6Busulfan 6blinatumomab 5Rituximab 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3Whole-Body Irradiation 3Methotrexate 3Darbepoetin alfa 3Alemtuzumab 3ponatinib 2ibrutinib 2entrectinib 2alectinib 2Thiotepa 2Therapeutics 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Everolimus 2Early Intervention, Educational 2Bone Marrow Transplantation 2Antilymphocyte Serum 2vandetanib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × venetoclax × Other hematologic neoplasm × Clear all
NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Georgetown University

Phase 2 Active not recruiting
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

AbbVie

Phase 2 Recruiting
110 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02265731 2021-08-02

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

AbbVie

Phase 1/2 Completed
38 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡